Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

ABSTRACT:

Background

We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosolized monobactam antibiotic]) in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) airway infection.

Methods

In this randomized, double-blind, placebo-controlled, international study (AIR-CF1 trial; June 2005 to April 2007), patients (n = 164; >or= 6 years of age) with FEV(1) >or= 25% and

SUBMITTER: Retsch-Bogart GZ 

PROVIDER: S-EPMC2818415 | biostudies-literature | 2009 May

REPOSITORIES: biostudies-literature